Chronic Traumatic Encephalopathy

Abstract

Chronic traumatic encephalopathy is a progressive neurodegenerative disease and a late form of traumatic brain injury, associated with a history of repetitive head impacts. It belongs to cognitive psychology because its toll is chiefly cognitive and behavioural: memory, executive function, and mood are the domains most eroded as pathology accumulates over decades. Its defining lesion is a distinctive deposition of hyperphosphorylated tau protein in neurons clustered around small vessels at the depths of the cortical sulci, a pattern that separates it from Alzheimer's disease. Diagnosis is at present certain only at autopsy, so the in-life clinical construct — traumatic encephalopathy syndrome — and tau imaging are active fronts. Chronic traumatic encephalopathy is best understood as the cumulative, delayed end of the head-impact spectrum rather than the result of any single blow.

Keywords: chronic traumatic encephalopathy, tauopathy, repetitive head impact

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease defined by the build-up of an abnormal form of the tau protein in a pattern tied to a life of repeated blows to the head (McKee et al., 2016). It was first described in boxers, under the older names *punch-drunk* syndrome and *dementia pugilistica*, and returned to prominence when the same pathology was found in the brains of American-football players and other contact-sport athletes (Corsellis et al., 1973), (Omalu et al., 2005). What makes CTE a subject for cognitive psychology, rather than pathology alone, is that its disease is felt as a slow change in *thinking* and *behaviour* — in memory, judgement, mood, and self-control — that can begin years or decades after the impacts have stopped (Stern et al., 2013). The clinical problem of CTE is, in the end, a cognitive one.

What Chronic Traumatic Encephalopathy Is

Chronic traumatic encephalopathy is a progressive *tauopathy* — a disease in which the tau protein, normally a scaffold that stabilises the internal transport skeleton of a neuron, becomes abnormally phosphorylated, detaches, and aggregates into toxic deposits that spread and kill cells over time (McKee et al., 2015). What distinguishes CTE from other tauopathies is not the protein but its *placement*. The 2016 consensus criteria, drawn up under the National Institute of Neurological Disorders and Stroke, defined a single pathognomonic lesion: hyperphosphorylated tau in neurons, with or without glial cells, distributed around small blood vessels and concentrated at the depths of the cortical sulci, in an irregular pattern (McKee et al., 2016). It is this signature — depth-of-sulcus, perivascular, patchy — that a neuropathologist looks for, and its distribution is unlike the even cortical spread of Alzheimer's disease.

That the defining lesion sits where it does is the central clue to cause. When the head is struck or rapidly rotated, mechanical strain does not fall evenly through the brain; it concentrates at the tissue interfaces and around the stiff walls of penetrating vessels, and computational and animal models suggest strain is greatest at exactly the sulcal depths where the tau is later found (Tagge et al., 2018). CTE is therefore understood as a disease *seeded* by the physics of repetitive impact and then propagated by the self-spreading behaviour of misfolded tau, long after the impacts themselves have ceased (Smith et al., 2013).

A crucial and often misunderstood feature is that CTE is, at present, a *post-mortem* diagnosis. The pathognomonic lesion can be confirmed only in tissue, so a living person cannot yet be told with certainty that they have the disease (McKee et al., 2016). To describe the syndrome as it appears in life, researchers use a separate clinical construct — *traumatic encephalopathy syndrome* — whose criteria were first proposed for research and later formalised through a second NINDS consensus process (Montenigro et al., 2014), (Katz et al., 2021). Keeping the pathology (CTE) and the in-life clinical picture (traumatic encephalopathy syndrome) distinct is essential to reading the evidence honestly.

How Repetitive Impact Becomes a Spreading Disease

The link from a blow to the head to a progressive brain disease runs through tau. A single traumatic brain injury can trigger tau pathology, and a career of repeated sub-concussive impacts — the routine, symptomless collisions of a contact sport, not only the diagnosed concussions — appears to be the stronger driver (Mez et al., 2020). The mechanical event injures axons and the small vessels that thread the cortex; the strain concentrated at the sulcal depths is thought to be where tau is first phosphorylated and begins to aggregate (Tagge et al., 2018). What turns local injury into a *disease* is that misfolded tau can act as a template, inducing normal tau in neighbouring and connected neurons to misfold in turn, so the pathology propagates through the brain's networks over years (Smith et al., 2013).

McKee and colleagues turned this spread into a four-stage scheme. In *stage I* the tau lesions are focal, confined to one or a few sulcal depths, usually in the frontal cortex, and the person is often asymptomatic or reports only headache and poor concentration. By *stage II* the lesions have multiplied and spread to nearby regions; by *stage III* they involve the medial temporal lobe, including the structures that support memory; and in *stage IV* the pathology is widespread with marked cortical atrophy and dementia (McKee et al., 2013). The staging matters because it links the *amount* and *location* of tau to the *severity* of the cognitive and behavioural syndrome, giving the disease the same dose-graded structure as its exposure. The spread through the medial temporal lobe in particular explains why the memory failures of advanced CTE resemble, superficially, those of Alzheimer's disease (McKee et al., 2015).

The Cognitive Cost of the Disease

The cognitive and behavioural syndrome of CTE has a recognisable shape. Two broad presentations are described: one that begins earlier in life and is dominated by *behavioural and mood* change — impulsivity, aggression, depression, and loss of control — and one that begins later and is dominated by *cognitive* decline in memory, executive function, and attention (Stern et al., 2013). Executive dysfunction is prominent and disabling: the capacity to plan, to inhibit an impulse, to hold a goal against distraction in working memory, and to judge the consequences of one's actions erodes, and it does so in a way that can leave over-learned knowledge and language relatively spared until late (Montenigro et al., 2014).

The four-stage scheme, first set out from a series of athlete brains and later formalised, maps the *spread* of tau onto the *severity* of the clinical picture (Table 1).

Table 1

The McKee Neuropathological Staging of Chronic Traumatic Encephalopathy

Note. Stages summarised from the athlete series that first described the progressive tauopathy (McKee et al., 2009) and the four-stage scheme that formalised it (McKee et al., 2013). The clinical columns describe typical, not invariant, presentations; individuals vary widely at every stage.

This profile is not accidental. The disease begins in and spreads through the frontal cortex and the medial temporal lobe — the substrates, respectively, of executive control and of episodic memory — so the functions it erodes are precisely those those regions support (McKee et al., 2013). The slowing of processing speed and the fraying of attention seen in the syndrome follow from the same distributed damage that any traumatic brain injury inflicts on long-range connections. What makes CTE distinctive among injuries is its *trajectory*: where a single injury tends to improve or stabilise, CTE, as a neurodegenerative disease, tends to progress, so a person's memory and self-control worsen over years even with no further impact (Stern et al., 2013).

Worked Example

If CTE is truly driven by cumulative impact, then the *amount* of exposure should predict the *odds* of disease — a dose-response relationship. Mez and colleagues tested this directly in a large brain-donor series and found that the odds of CTE rose with each additional year of American-football play, estimating roughly a 30% increase in the odds per year of play (Mez et al., 2020). Odds that grow by a fixed *proportion* with each unit of exposure compound geometrically, exactly like interest. If a single year multiplies the odds by a factor $r$, then $Y$ years multiply them by:

$$\text{OR}(Y) = r^{\,Y}$$

Take the reported per-year factor $r = 1.30$. For a player with $Y = 10$ years of exposure, the cumulative odds ratio relative to no play is:

$$\text{OR}(10) = 1.30^{10} \approx 13.8$$

so ten years of play is associated with odds of CTE roughly fourteen times higher than the baseline. A natural way to read a compounding rate is to ask how long it takes the odds to *double*. Setting $r^{Y} = 2$ and solving gives:

$$Y_{2} = \frac{\ln 2}{\ln r} = \frac{0.693}{\ln 1.30} \approx \frac{0.693}{0.262} \approx 2.6 \text{ years}$$

so on this estimate the odds of CTE double for roughly every two-and-a-half years of play — the finding Mez and colleagues expressed as a doubling of risk per 2.6 years of exposure (Mez et al., 2020). The worked figure repays careful reading, because it also marks the limits of the claim. An *odds ratio* is not a probability: it says CTE becomes far more likely with exposure among brains that came to a brain bank, but it cannot, on its own, tell an individual player their absolute chance of disease. The donor brains were not a random sample of players — families often donated precisely because they suspected disease — so the baseline is unknown and the true population risk cannot be read from these odds (Asken et al., 2017). The mathematics of compounding exposure is clean; the epidemiology it sits inside is not yet settled.

Discussion

The scientific interest of CTE for cognitive psychology is that it is a disease of *history* written into tissue. Unlike an acute traumatic brain injury, whose deficits follow immediately from the damage, CTE encodes a lifetime of impacts as a slow, spreading tauopathy whose cognitive expression may not appear until decades later (Stern et al., 2013). The reliable erosion of executive control and episodic memory in advanced disease is the predictable signature of pathology that begins in the frontal cortex and marches through the medial temporal lobe, and it offers, like any lesion study, a lesson about the healthy mind: that the functions most vulnerable to slow degeneration are the same distinctly human control processes that a single injury also strikes first (McKee et al., 2013).

The three demonstrations on this page track that idea at three resolutions. The lesion display shows how the defining pathology concentrates at the sulcal depth around a vessel, distinguishing CTE from the even cortical spread of Alzheimer's disease; the staging display shows how tau spreads from focal frontal lesions to widespread cortical disease, and how the cognitive syndrome tracks that spread; and the dose-response display shows how the odds of disease compound with years of exposure. Where the account remains genuinely open is at the boundary between *association* and *cause*. That repetitive head impact is associated with CTE is now supported by consistent neuropathology across sports and countries (Mez et al., 2017), (Ling et al., 2017), (Bieniek et al., 2015). But how often exposure leads to disease, why some heavily-exposed players never develop it, and how tightly the pathology maps onto symptoms in life are all unresolved, and the field has been candid about the selection biases and gaps that make them hard to answer (Asken et al., 2017), (Bieniek et al., 2020).

Cognitive Implications

The clearest cognitive lesson of CTE is that a mechanical cause can produce a *degenerative* effect — that the brain can be set on a course of progressive decline by events that ended long before. This reframes the head impacts of a contact-sport career not as discrete injuries that heal but as an accumulating exposure whose cost is paid, with interest, decades later (Mez et al., 2020). For cognitive assessment, it means that a history of exposure becomes part of the differential when an older adult presents with executive and memory decline, and that the profile of CTE — early behavioural change, prominent executive dysfunction — must be distinguished from the amnestic-first profile of Alzheimer's disease, even though the two can share features and can co-occur (Ling et al., 2017).

A second implication concerns the difference between a *disease* and its *syndrome*. Because CTE can be confirmed only at autopsy, everything measured in a living person — memory scores, mood, imaging — is a measure of *traumatic encephalopathy syndrome*, the clinical construct, not of the pathology itself (Katz et al., 2021). The gap between the two is a standing methodological caution: a person can carry the pathology without the syndrome, or show the syndrome for reasons other than CTE, so claims that link symptoms directly to disease in the living must be read with care. Closing that gap — finding a biomarker that detects the tau of CTE in life — is the central goal of current work, and the clearest example of why the distinction between what is seen in tissue and what is measured in behaviour matters (Stern et al., 2019).

Current Directions

Three fronts are active. The first is *diagnosis in life*. Because the disease is defined post-mortem, the field's central ambition is a biomarker that detects CTE tau in the living brain; positron-emission tomography with tau-binding tracers has shown higher signal in former players in regions consistent with the pathology, but the tracers were designed for Alzheimer's tau and their accuracy for CTE is not yet established (Stern et al., 2019). The second is *epidemiology*. The large case series that made CTE famous were drawn from brain banks enriched for disease, so the true prevalence and the absolute risk per unit of exposure remain unknown; community-based and cohort studies that avoid this selection are the priority, and some already temper the strongest claims (Bieniek et al., 2020), (Asken et al., 2017).

The third front is *mechanism and causation*. Establishing that repetitive impact does not merely correlate with but *causes* CTE, and mapping the path from strain to tau to spread, draws on animal and blast models and on the wider question of how a single or repeated traumatic brain injury raises the long-term risk of neurodegeneration (Tagge et al., 2018), (Gardner et al., 2015), (Goldstein et al., 2012). Across all three fronts the shift is the same: from a striking series of post-mortem case reports toward the harder, slower science of prevalence, causation, and detection that will decide how large a public-health problem CTE truly is (Mez et al., 2017).

Common Misconceptions

Chronic traumatic encephalopathy can be diagnosed in a living person.

Not yet with certainty. CTE is defined by a pathological lesion that can be confirmed only in brain tissue after death. What is assessed in life is traumatic encephalopathy syndrome, a clinical construct, and finding a biomarker to detect the disease in the living is an active research goal (McKee et al., 2016), (Stern et al., 2019).

A single concussion causes CTE.

The disease is associated with repetitive head impacts over time, including the routine sub-concussive collisions of contact sport, not with one concussion. The odds of disease rise with the cumulative years of exposure rather than with any single blow (Mez et al., 2020).

CTE is just a form of Alzheimer's disease.

No. Both involve tau, but the distribution differs: CTE tau concentrates at the depths of the cortical sulci around small vessels in an irregular pattern, whereas Alzheimer's tau spreads more evenly and is accompanied by amyloid plaques. The two are distinct diseases that can also co-occur (McKee et al., 2016), (Ling et al., 2017).

Because famous players had CTE, most players will get it.

That does not follow. The best-known series came from brain banks that families donated to precisely because disease was suspected, so they cannot give a population rate. The true prevalence and individual risk are genuinely uncertain and are the target of ongoing unbiased study (Asken et al., 2017), (Bieniek et al., 2020).

Glossary

Astrocyte.

A star-shaped support cell of the brain; in CTE, tau can accumulate in astrocytes as well as neurons, part of the disease's characteristic mixed cellular pathology.

Attention.

The selection and sustaining of mental focus; among the cognitive functions eroded as CTE pathology spreads through the frontal cortex.

Chronic traumatic encephalopathy (CTE).

A progressive neurodegenerative tauopathy associated with a history of repetitive head impacts, defined by a distinctive pattern of tau deposition and confirmed only at autopsy.

Dementia pugilistica.

The historical name for the CTE-like syndrome first described in boxers, also called punch-drunk syndrome; the earliest recognition of the disease now called CTE.

Dose-response relationship.

A pattern in which the likelihood or severity of an outcome rises with the amount of exposure; in CTE, the odds of disease increase with the cumulative years of contact-sport play.

Executive function.

The set of frontal control processes — planning, inhibition, working memory, and flexible switching — that are prominently and disablingly impaired in CTE.

Hyperphosphorylated tau.

Tau protein carrying excess phosphate groups, which causes it to detach from the neuron's transport skeleton and aggregate into the toxic deposits that define CTE and other tauopathies.

Long-term memory.

The durable store of knowledge and experience; its episodic component fails as CTE tau invades the medial temporal lobe in later stages.

Medial temporal lobe.

The inner temporal region, including the hippocampus, that supports episodic memory; its involvement in CTE stage III explains the memory decline of advanced disease.

Neurodegenerative disease.

A disorder in which neurons progressively lose function and die over time; CTE is neurodegenerative, so its cognitive toll worsens even after head impacts have stopped.

Perivascular.

Situated around a blood vessel; the tau of CTE clusters perivascularly, around the small penetrating vessels at the depths of the cortical sulci.

Processing speed.

The rate at which the brain takes in and acts on information; slowed in CTE as in other injuries that degrade long-range connections.

Repetitive head impact.

The cumulative exposure to blows and jolts, including symptomless sub-concussive collisions, that is the recognised risk factor for CTE.

Sulcal depth.

The deepest point of a fold (sulcus) in the cortex; the site where CTE tau concentrates, thought to be where mechanical strain is greatest during impact.

Tauopathy.

A neurodegenerative disease characterised by the abnormal aggregation of tau protein; CTE is a tauopathy, as are Alzheimer's disease and several others, distinguished by where the tau is deposited.

Traumatic brain injury.

A disruption of brain function caused by an external mechanical force; CTE sits at the cumulative, delayed end of its spectrum.

Traumatic encephalopathy syndrome (TES).

The in-life clinical construct used to describe the cognitive and behavioural syndrome attributed to CTE, defined by consensus criteria because the pathology itself can be confirmed only after death.

Working memory.

The system that holds and manipulates information over seconds; its failure contributes to the executive dysfunction prominent in CTE.

Key Researchers

Ann McKee

Neuropathologist at Boston University School of Medicine who defined the pathological staging of chronic traumatic encephalopathy and chaired the first consensus meeting to establish its neuropathological diagnostic criteria. ORCID

Jesse Mez

Behavioural neurologist at Boston University who led the large clinicopathological case series of CTE in American-football players and the dose-response analysis linking years of play to the odds of disease. ORCID

Christopher J. Nowinski

Co-founder of the Concussion Legacy Foundation and co-author of the foundational CTE case series, who built the brain-donation programme that supplied much of the case material. ORCID

Bennet Omalu

(b. 1968). Forensic pathologist who published the first case of chronic traumatic encephalopathy in a National Football League player, bringing the disease to wide attention in the modern sporting context. Wikipedia

Douglas H. Smith

Director of the Center for Brain Injury and Repair at the University of Pennsylvania, whose work frames single and repetitive traumatic brain injury as substrates of dementia and connects the mechanics of impact to chronic tauopathy. ORCID

Thor D. Stein

Neuropathologist at Boston University and the VA Boston Healthcare System, co-author of the CTE staging and neuropathology work, studying the tau and mixed pathology of the brain bank. ORCID

Frequently Asked Questions

What is chronic traumatic encephalopathy?

It is a progressive neurodegenerative disease associated with a history of repeated head impacts, such as those in contact sports or military service. It is defined by a distinctive build-up of tau protein in the brain and, at present, can be diagnosed with certainty only after death.

What causes it?

The recognised risk factor is repetitive head impact over time, including the routine sub-concussive collisions of a contact-sport career, not only diagnosed concussions. The mechanical strain of impact is thought to seed abnormal tau, which then spreads through the brain over years as a self-propagating disease.

How is CTE different from Alzheimer's disease?

Both involve the tau protein, but its distribution differs. In CTE the tau clusters at the depths of the cortical folds around small blood vessels in an irregular pattern, while in Alzheimer's disease it spreads more evenly and is accompanied by amyloid plaques. They are distinct diseases that can also occur together.

Can CTE be diagnosed while a person is alive?

Not yet with certainty. The defining lesion can be confirmed only in brain tissue after death. The syndrome seen in life is called traumatic encephalopathy syndrome, and developing an imaging or fluid biomarker to detect the disease in living people is a central goal of current research.

What are the symptoms?

Two broad patterns are described. One begins earlier and is dominated by changes in behaviour and mood, including impulsivity, aggression, and depression. The other begins later and is dominated by cognitive decline in memory, attention, and executive function. The symptoms tend to progress over years.

Does every athlete who plays a contact sport get CTE?

No. The odds of disease rise with the cumulative years of play, but many exposed players never develop it, and the true rate is uncertain. Much of the best-known evidence came from donated brains of people already suspected of disease, so it cannot give a population risk.

Is a single concussion enough to cause it?

The disease is linked to repeated impacts accumulated over time, not to one concussion. A single injury can trigger tau pathology and raises the long-term risk of neurodegeneration, but CTE specifically is associated with a history of repetitive exposure.

Can chronic traumatic encephalopathy be treated?

There is at present no treatment that stops or reverses the underlying disease. Care focuses on managing symptoms, such as mood and cognitive difficulties, and on prevention through reducing head impacts. Because diagnosis in life is not yet certain, prevention and long-term monitoring are the main tools.

Support Organizations

References